Compare HMH & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMH | EVMN |
|---|---|---|
| Founded | 2021 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil and Gas Field Machinery | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.2M | 284.5M |
| IPO Year | 2024 | 2025 |
| Metric | HMH | EVMN |
|---|---|---|
| Price | $10.98 | $7.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $22.43 | $21.89 |
| AVG Volume (30 Days) | 299.6K | ★ 942.1K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.23 |
| EPS | ★ 1.56 | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.86 | $40.00 |
| P/E Ratio | $7.19 | ★ N/A |
| Revenue Growth | N/A | ★ 85.71 |
| 52 Week Low | $10.31 | $4.94 |
| 52 Week High | $22.34 | $33.20 |
| Indicator | HMH | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 29.04 | 50.80 |
| Support Level | $10.31 | $4.94 |
| Resistance Level | $19.97 | $7.21 |
| Average True Range (ATR) | 1.07 | 0.65 |
| MACD | -0.14 | 0.09 |
| Stochastic Oscillator | 7.22 | 41.48 |
HMH Holding Inc is a provider of offshore and onshore drilling equipment and services in the United States and Norway. Its services include sales of projects and products including drilling equipment packages for newbuild or a reactivated drilling rig, and individual or grouped components of drilling and pressure control equipment. The company also offers aftermarket services including services and replacement parts on installed equipment and integrated digital solutions. The company sells equipment and services to drilling contractors; operators, including both oil and gas E&P companies and mining companies onshore and offshore; and manufacturers, consisting of shipyards.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.